Suppr超能文献

小檗碱在糖尿病性骨病中的治疗潜力。

Possible therapeutic potential of berberine in diabetic osteopathy.

机构信息

Sinhgad College of Pharmacy, Post-Graduate Research Department, Off Sinhgad Road, Vadgaon (Bk), Pune 411 041, Maharashtra, India.

出版信息

Med Hypotheses. 2012 Oct;79(4):440-4. doi: 10.1016/j.mehy.2012.06.016. Epub 2012 Jul 26.

Abstract

Diabetic osteopathy is a complication that leads to decreased bone mineral density, bone formation and having high risk of fractures that heals slowly. Diabetic osteopathy is a result of increase in osteoclastogenesis and decrease in osteoblastogenesis. Various factors viz., oxidative stress, increased inflammatory markers, PPAR-γ activation in osteoblast, activation of apoptotic pathway, increased glucose levels and inhibitory effect on parathyroid hormone etc. are mainly responsible for decreased bone mineral density. Berberine is an isoquinoline alkaloid widely used in Asian countries as a traditional medicine. Berberine is extensively reported to be an antioxidant, anti-inflammatory, antidiabetic, and having potential to treat diabetic complications and glucocorticoid induced osteoporosis. The osteoclastogenesis decreasing property of berberine can be hypothesized for inhibiting diabetic osteopathy. In addition, chronic treatment of berberine will be helpful for increasing the osteoblastic activity and expression of the modulators that affect osteoblastic differentiation. The apoptotic pathways stimulated due to increased inflammatory markers and nucleic acid damages could be reduced due to berberine. Another important consideration that berberine is having stimulatory effect on glucagon like peptide release and insulin sensitization that will be helpful for decreasing glucose levels and therefore, may exerts osteogenesis. Thiazolidinediones show bone loss due to activation of PPAR-γ in osteoblasts, whereas berberine stimulates PPAR-γ only in adipocytes and not in osteoblasts, and therefore the decreased bone loss due to use of thiazolidinediones may not be observed in berberine treatment conditions. Berberine decreases the advanced glycation end-products (AGE) formation in diabetic condition which will be ultimately helpful to decrease the stiffness of collagen fibers due to AGE-induced cross linking. Lastly, it is also reported that berberine has inhibitory effect on parathyroid hormone and enhances marker genes like osteocalcin, which are responsible for the osteoblastic activity. From these evidences, we hypothesized that berberine may have potential in the treatment of diabetic osteopathy.

摘要

糖尿病性骨病是一种导致骨密度降低、骨形成减少以及骨折愈合缓慢的并发症。糖尿病性骨病是破骨细胞生成增加和成骨细胞生成减少的结果。各种因素,如氧化应激、炎症标志物增加、成骨细胞中过氧化物酶体增殖物激活受体-γ(PPAR-γ)的激活、凋亡途径的激活、葡萄糖水平升高以及对甲状旁腺激素的抑制作用等,主要负责骨密度降低。小檗碱是一种广泛应用于亚洲国家的异喹啉生物碱,作为传统药物。小檗碱被广泛报道具有抗氧化、抗炎、抗糖尿病作用,并具有治疗糖尿病并发症和糖皮质激素诱导性骨质疏松症的潜力。小檗碱降低破骨细胞生成的特性可用于抑制糖尿病性骨病。此外,小檗碱的慢性治疗将有助于增加成骨细胞的活性和影响成骨细胞分化的调节剂的表达。由于小檗碱,由于炎症标志物增加和核酸损伤刺激的凋亡途径可以减少。另一个重要的考虑因素是,小檗碱对胰高血糖素样肽释放和胰岛素敏化具有刺激作用,这将有助于降低血糖水平,因此可能发挥成骨作用。噻唑烷二酮类药物由于在成骨细胞中激活过氧化物酶体增殖物激活受体-γ(PPAR-γ)而导致骨丢失,而小檗碱仅在脂肪细胞中刺激 PPAR-γ,而不在成骨细胞中,因此在使用噻唑烷二酮类药物时观察到的骨丢失减少可能不会在小檗碱治疗条件下观察到。小檗碱可减少糖尿病状态下的晚期糖基化终产物(AGE)形成,这将有助于由于 AGE 诱导的交联而减少胶原纤维的僵硬。最后,据报道,小檗碱对甲状旁腺激素具有抑制作用,并增强了骨钙素等标记基因,这些基因负责成骨细胞的活性。根据这些证据,我们假设小檗碱可能在治疗糖尿病性骨病方面具有潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验